|
Synonyms: compound 127 [PMID: 37402343] | VI-176 [1-2]
Compound class:
Synthetic organic
Comment: Odemsertib is the INN for a serine/threonine kinase inhibitor that targets IRAK1/4 for immunosuppression effect [1]. It is the active form of the oral prodrug odemsertib etifosfate (R906289; RG289; Rigel Therapeutics). The company code for odemsertib is R835.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bai YR, Yang WG, Hou XH, Shen DD, Zhang SN, Li Y, Qiao YY, Wang SQ, Yuan S, Liu HM. (2023)
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases. Eur J Med Chem, 258: 115606. [PMID:37402343] |
|
2. Taylor V, Issakani S, Young C. (2021)
Compounds and method for treating cytokine release syndrome. Patent number: WO2021026451A1. Assignee: Rigel Pharmaceuticals Inc. Priority date: 07/08/2020. Publication date: 11/02/2021. |